Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Safety and tolerability of the vepdegestrant in breast cancer

Erika Hamilton • 20 Oct 2023
ESMO 2023
Breast Cancer Vepdegestrant
VERITAC VERITAC-3

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the Phase I dose escalation data from a Phase I/II study (NCT04072952) that aims to assess the safety and efficacy of vepdegestrant (ARV-471) in heavily pre-treated patients with ER2+/HER2- locally advanced or metastatic breast cancer. The drug was very well-tolerated: no dose-limiting toxicities were observed at any dose level. Of 83 patients, 24% had any grade of nausea. 24% experienced fatigue and 13% experienced arthralgia (all Grade 1 or 2). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erika Hamilton

1:05
CAMBRIA 1: camizestrant ER+/HER2- early breast cancer
Erika Hamilton • 12 Dec 2023
2:03
The landscape of oral SERDs and their potential in ER+ breast cancer
Erika Hamilton • 12 Dec 2023
1:56
Vepdegestrant + palbociclib in ER+ metastatic breast cancer: Phase Ib trial results
Erika Hamilton • 12 Dec 2023
1:08
Non-adherence in breast cancer treatment
Erika Hamilton • 20 Oct 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals